Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: LGND stock price vs QCOM: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at QCOM's multiple
Needs QCOM P/E.
Implied fair value · at LGND's multiple
Needs LGND P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · QCOM FY 2025 (ended Sep 28, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Bear
$101.45
Base
$119.35
Bull
$137.25
QUALCOMM INC/DE · implied price per share
Bear
$95.67
Base
$112.55
Bull
$129.43
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.25x
0.76x
Net debt / EBITDA
Leverage against operating earnings
-2.31x
0.40x
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
$10.16B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Royalty Pharma plc
LGND vs RPRX
Sarepta Therapeutics, Inc.
LGND vs SRPT
INCYTE CORP
LGND vs INCY
EXELIXIS, INC.
LGND vs EXEL
Broadcom Inc.
LGND vs AVGO
INTEL CORP
LGND vs INTC
NVIDIA CORP
LGND vs NVDA
TEXAS INSTRUMENTS INC
LGND vs TXN
ADVANCED MICRO DEVICES INC
LGND vs AMD
Qorvo, Inc.
LGND vs QRVO
$252.03M
$16.18B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe LGND can sustain 60.4% revenue growth and preserve its 97.6% gross margin, then hold or accumulate selectively because its premium economics could justify some of the valuation gap; if growth normalizes or margins compress, the current price looks vulnerable given the -32.5% P/E-based downside.
LGND is trading above QCOM-implied valuation range and well above the DCF range, even though it sits near the upper end of its own historical band. The market is pricing in LGND’s exceptional margins and growth, but the current price still implies meaningful downside versus the P/E-based fair value estimate.
Supporting Metrics
Price unavailable
